HIV virus floating on DNA background, HIV vaccine and treatment, HIV treatment treatment concept 3D rendering
getty
A decades-long effort to teach the immune system how to produce broadly protective antibodies now has its strongest results in primates, offering a new path toward one of medicine’s most elusive vaccines.
Some 40 years ago, at the Second International AIDS Conference in Paris, I argued that an effective HIV vaccine was unlikely to arrive soon. Most vaccines work by teaching the immune system to recognize a virus before infection. HIV is different. Once established, neither antibodies nor immune cells completely eliminate it. I believed that solving this problem would require a much deeper understanding of how the immune system produces protective antibodies.
Today, a solution may finally emerge. A new vaccine strategy has now generated broadly neutralizing antibodies in non-human primates, something no HIV vaccine has achieved before.
Why HIV has defied vaccines
Most successful vaccines teach the immune system to recognize a virus before it causes disease. Once exposed to the actual germ, the memory’s immune cells quickly produce antibodies that stop the infection from spreading.
HIV presents a different challenge. The virus is constantly mutating, producing enormous genetic diversity around the world. Antibodies that recognize one strain often fail against another. An effective vaccine must therefore produce broadly neutralizing antibodies, rare antibodies capable of recognizing many different variants of HIV. Only a small fraction of people infected with HIV ever develop these broadly neutralizing antibodies, and it usually takes years of infection. For years, researchers knew these broadly neutralizing antibodies existed. The challenge was to find a way to convince the immune system to do them through vaccination rather than infection.
Teaching the immune system step by step
The new strategy abandons the idea that a single vaccine can accomplish this task. Instead, it guides the immune system through a carefully designed series of immunizations based on how antibodies naturally evolve. The process is designed to direct an otherwise random search toward a very specific goal.
The first vaccine activates rare precursor B cells that have the potential to become broadly neutralizing antibody-producing cells. Then, early booster shots select cells that can recognize a key region of the HIV surface protein. Later boosters expose these cells to slightly different versions of the protein, driving the mutations and refinements needed to recognize an increasingly diverse set of HIV strains.
Each stage performs a different job: it activates the right progenitor cells, selects the cells that bind HIV, improves their ability to recognize the target, and expands the cells that acquire broad neutralizing activity. Instead of asking the immune system to immediately make the perfect antibody, the vaccine teaches it gradually, like a series of increasingly difficult lessons.
What the Study Found
The sequential vaccine regimen was tested in rhesus macaques, a particularly challenging model because the immune precursor cells needed for this type of response are even rarer than in humans. More than half of the animals developed the desired class of broadly neutralizing antibodies. In 44 percent of the animals, these antibodies appeared in the bloodstream and neutralized various strains of HIV.
One animal produced levels of antibodies predicted to provide 75 to 90 percent protection against various strains of HIV. Several others reached levels expected to provide about 50 percent protection. The best antibody responses resembled the rare broadly neutralizing antibodies that only a small number of people develop naturally after years of living with HIV.
Just as important, the vaccine didn’t just produce antibodies. It generated long-lived memory B cells that continued to mature with each booster, showing that the immune system could be guided through a series of changes required to produce broadly protective antibodies.
Beyond HIV
The significance of the study extends beyond a single virus. The germline targeting strategy was designed specifically for HIV because conventional vaccine approaches have repeatedly failed. But the same principle could be applied to other rapidly evolving viruses that have resisted traditional vaccine development.
Much work remains before an HIV vaccine reaches patients. The current study was conducted in nonhuman primates, and the full vaccination schedule still requires optimization before widespread clinical use. Some elements of the strategy are already being evaluated in human trials, providing an important next step toward translation.
For decades, HIV vaccine research has been defined by setbacks. This study demonstrates something that many researchers once doubted was possible: the immune system can be deliberately guided to produce the antibodies needed to protect against one of the world’s most challenging viruses.
